HOME >> BIOLOGY >> NEWS
Applied Biosystems launches Assays-on-Demand SNP genotyping and gene expression products

FOSTER CITY, CA - July 10, 2002 - Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, today announced the launch of its biologically informative Assays-on-Demand products, the most comprehensive product line yet introduced based on information derived from the human genome. This is the first commercial product line to emerge from genomic data from both the public and private sector human genome sequencing projects. The Assays-on-Demand products leverage data from Celera Genomics Group (NYSE:CRA), Applied Biosystems' sister business group, The SNP Consortium (TSC), the National Center for Biotechnology Information (NCBI), and the Japanese SNP database (JSNP).

The Assays-on-Demand products represent the broadest collection of functionally validated, ready-to-use assays based on the human genome and are the first commercial products resulting from the Applera Genomics Initiative announced in July 2001. The initial set consists of 77,000 assays for SNP genotyping and 4400 assays for quantitative gene expression analysis and is designed using Applied Biosystems' bioinformatics pipeline and proprietary software algorithms. For every assay produced, the target sequence is subjected to an extensive selection and quality control process to screen for those assays that are specific to the gene or SNP of interest for improved specificity and optimal assay design. Additional assays for both gene expression and SNP genotyping are expected to be released on an ongoing basis over the coming months through the Applied Biosystems Knowledge Business. Ultimately, Applied Biosystems plans to offer a genome-wide selection of off-the-shelf SNP assays and a gene expression assay for nearly every human gene and major splice variant.

"By combining information discovered in the sequencing of the human genome with our subsequent resequencing work through the Applera Genomics Initiative, the Applied Biosystems Knowledge Business is providing information-rich p
'"/>

Contact: Lori Murray, Applied Biosystems
murrayla@appliedbiosystems.co
650-638-6130
Porter Novelli
10-Jul-2002


Page: 1 2 3 4 5

Related biology news :

1. Applied Mathematical Models in Human Physiology
2. Dana-Farber launches Center for Applied Cancer Science
3. Applied Biosystems announces $250,000 grant program for SNP genotyping studies
4. Applied Biosystems announces enhancements to Celera Discovery System and new subscription model
5. Applied Biosystems announces SNPlex ultra high throughput genotyping system
6. Applied Biosystems and Immune Tolerance Network announce immunology research agreement
7. Applied Biosystems introduces new chemistries to increase DNA sequencing productivity
8. Applied Biosystems introduces new system for protein and metabolite analysis
9. Hutch Researcher Wins Nobel Prize Of Applied Research
10. Biosphere Lessons Can Be Applied To Space, Former Crew Co-Captain Says
11. NHGRI launches Centers for Excellence in Ethical, Legal, and Social Implications Research

Post Your Comments:
(Date:4/14/2015)... 14, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... 2015 New York Design Awards under the category  ,Product ... City Design Awards are part of a global multi-disciplinary ... ratings from the marketplace, industry and judging panel. Winners ...
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
(Date:4/6/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM ... NXT-ID introduces a new revolutionary method and system ... use of miniature antenna modules for multiple purposes ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
(Date:4/21/2015)... April 21, 2015 The North ... in 2014 to $605.1 million by 2019, at a ... Browse through the TOC of North ... of the industry trends and segments, with help of ... Early buyers will receive 10% customization ...
(Date:4/21/2015)... , April 21, 2015 Merrimack Pharmaceuticals, ... from a multi-arm Phase 1 study of MM-141, a ... presented in an oral session by Dr. Mansoor ... Cancer Research Annual Meeting in Philadelphia, PA. ... of MM-141 as a monotherapy and in combination with ...
(Date:4/21/2015)... PROVO, Utah , April 21, 2015  Tute Genomics, ... the hiring of Josh Forsythe as VP of ... that has witnessed a significant expansion in its commercial operations ... " Josh Forsythe is a ... Robison , MD MBA, CEO of Tute Genomics. "Josh,s vast ...
(Date:4/21/2015)... York (PRWEB) April 21, 2015 Progyny, ... Fertility Authority, LLC, announced that it has secured additional ... (KPCB), TPG Biotech, SR One and Merck Serono Ventures. ... to provide patients the best fertility outcomes by aligning ... the largest online marketplace for families seeking fertility solutions ...
Breaking Biology Technology:North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 2North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 2First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 4First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 5Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 2
Cached News: